Ar - androgen receptor Gene

中文名称：雄激素受体

种属: Rattus norvegicus

同用名: Tfm; Andr

基因 ID: 24208 | 基因类型: protein coding

关于 Ar

Primary_assembly X: 63,104,771-63,273,925 forward strand.mRatBN7.2:CM026994.1

This gene has 1 transcript (splice variant), 277 orthologues, 8 paralogues and is associated with 62 phenotypes. Biased expression in Adrenal (RPKM 352.8), Uterus (RPKM 74.9) and 7 other tissues.

功能概要

该基因编码的蛋白可启动多种功能，包括雄激素结合活性；雄激素受体结合活性；和核受体活性。参与多个过程，包括细胞对激素刺激的反应；交配;和转录调控，DNA 模板化。位于多个细胞成分中，包括轴突；树突;和核。用于研究高血压；骨质疏松症；前列腺癌；前列腺癌;和前列腺肥大。急性肾衰竭和雄激素不敏感综合征的生物标志物。该基因的人类直系同源物与多种疾病有关，包括注意力缺陷多动障碍；品行障碍;性发育障碍（多发）；生殖器官癌（多发性）；和脊髓性肌萎缩症（多发性）。与人类 AR（雄激素受体）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables several functions, including androgen binding activity; Androgen Receptor binding activity; and nuclear receptor activity. Involved in several processes, including cellular response to hormone stimulus; mating; and regulation of transcription, DNA-templated. Located in several cellular components, including axon; dendrite; and nucleus. Used to study hypertension; osteoporosis; prostate adenocarcinoma; prostate cancer; and prostatic hypertrophy. Biomarker of acute kidney failure and androgen insensitivity syndrome. Human ortholog(s) of this gene implicated in several diseases, including attention deficit hyperactivity disorder; conduct disorder; disorder of sexual development (multiple); reproductive organ Cancer (multiple); and spinal muscular atrophy (multiple). Orthologous to human AR (Androgen Receptor). [provided by Alliance of Genome Resources, Apr 2022]

Ar 基因产物(1)

mRNA	Protein	Name
NM_012502.2	NP_036634.2	androgen receptor

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables androgen binding	IMP IMP: 通过突变表型推断	2341409	RGD
enables chromatin binding	IDA IDA: 通过直接分析推断	3499428	RGD
enables nuclear androgen receptor binding	IPI IPI: 通过物理相互作用推断	9710597	RGD
enables nuclear receptor activity	IDA IDA: 通过直接分析推断	2341409	RGD
enables protein binding	IPI IPI: 通过物理相互作用推断	12350225	RGD
enables protein domain specific binding	IPI IPI: 通过物理相互作用推断	17223690	RGD
enables ribonucleotide binding	IDA IDA: 通过直接分析推断	6193790	RGD
enables sequence-specific DNA binding	IDA IDA: 通过直接分析推断	10385402	RGD
enables signaling receptor binding	IPI IPI: 通过物理相互作用推断	11875111	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in androgen receptor signaling pathway	IMP IMP: 通过突变表型推断	2341409	RGD
involved in cellular response to follicle-stimulating hormone stimulus	IEP IEP: 通过表达模式推断	2502458	RGD
involved in cellular response to steroid hormone stimulus	IEP IEP: 通过表达模式推断	2341409	RGD
involved in copulation	IMP IMP: 通过突变表型推断	15178162	RGD
involved in drinking behavior	IMP IMP: 通过突变表型推断	28776866	RGD
involved in liver regeneration	IEP IEP: 通过表达模式推断	2598758	RGD
involved in locomotion	IMP IMP: 通过突变表型推断	28776866	RGD
involved in male courtship behavior	IMP IMP: 通过突变表型推断	15178162	RGD
involved in male sex differentiation	IMP IMP: 通过突变表型推断	2341409	RGD
involved in negative regulation of DNA-templated transcription	IDA IDA: 通过直接分析推断	10385402	RGD
involved in positive regulation of DNA-templated transcription	IDA IDA: 通过直接分析推断	10385402	RGD
involved in positive regulation of hippocampal neuron apoptotic process	IMP IMP: 通过突变表型推断	18289534	RGD
involved in positive regulation of locomotion	IMP IMP: 通过突变表型推断	28776866	RGD
involved in positive regulation of penile erection	IMP IMP: 通过突变表型推断	21315100	RGD
involved in prostate gland growth	IEP IEP: 通过表达模式推断	3628973	RGD
involved in reproductive behavior	IDA IDA: 通过直接分析推断	20392832	RGD
involved in response to environmental enrichment	IMP IMP: 通过突变表型推断	28776866	RGD
involved in response to estradiol	IEP IEP: 通过表达模式推断	10913783	RGD
involved in response to ethanol	IDA IDA: 通过直接分析推断	3678734	RGD
involved in response to insulin	IEP IEP: 通过表达模式推断	15596216	RGD
involved in response to muscle activity	IEP IEP: 通过表达模式推断	16286851	RGD
involved in response to nicotine	IEP IEP: 通过表达模式推断	27602328	RGD
involved in response to steroid hormone	IEP IEP: 通过表达模式推断	2644508	RGD
involved in response to testosterone	IEP IEP: 通过表达模式推断	10913783	RGD
involved in skeletal muscle hypertrophy	IMP IMP: 通过突变表型推断	7957162	RGD
involved in spermatogenesis	IMP IMP: 通过突变表型推断	15347734	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in axon	IDA IDA: 通过直接分析推断	12865346	RGD
located in cytosol	IDA IDA: 通过直接分析推断	3678734	RGD
located in dendrite	IDA IDA: 通过直接分析推断	12865346	RGD
located in nuclear matrix	IDA IDA: 通过直接分析推断	6466649	RGD
located in nucleus	IDA IDA: 通过直接分析推断	3678734	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Ar 蛋白结构

Androgen_recep

NR_DBD_AR

NR_LBD_AR

0
200
400
600
800
902 a.a.

蛋白主名

其他名称

androgen receptor

androgen receptor (Testicular feminization), same as Tfm	dihydrotestosterone receptor
nuclear receptor subfamily 3 group C member 4

相关产品

Approval

生物活性分子 (112)

目录号	产品名	作用方式	纯度	是否罕见病
HY-70002	Enzalutamide		99.96%	否
HY-13715	Norepinephrine		99.43%	是
HY-B0573	Propranolol hydrochloride	Antagonist	99.96%	是
HY-Y1269	Ammonium chloride, AR, 99.5%	Inhibitor	99.65%	是
HY-111372	Finerenone	Antagonist	99.66%	否
HY-B0573B	Propranolol	Antagonist	99.87%	是
HY-N0378	D-Mannitol		99.93%	是
HY-10064	Ticagrelor	Antagonist	99.98%	是
HY-13715A	Norepinephrine hydrochloride		99.95%	是
HY-N0092	Inosine	Agonist	99.67%	是
HY-16985	Darolutamide	Antagonist	99.30%	否
HY-16060	Apalutamide	Antagonist	99.93%	否
HY-14249	Bicalutamide		99.85%	否
HY-B1037	Salbutamol		99.92%	是
HY-13613	Dutasteride		99.83%	是
HY-13715B	Norepinephrine bitartrate monohydrate		99.75%	否
HY-19638A	Cangrelor tetrasodium	Antagonist	99.93%	否
HY-14300A	Vilanterol trifenatate	Agonist	99.61%	否
HY-15746	Dobutamine hydrochloride	Agonist	99.91%	是
HY-17627	Avacopan	Inhibitor	99.75%	是
HY-15142R	Doxorubicin hydrochloride (Standard)		/	否
HY-17042A	Cetirizine dihydrochloride	Antagonist	99.53%	是
HY-B0659A	Brimonidine tartrate	Agonist	99.14%	是
HY-10122	Silodosin	Antagonist	99.85%	是
HY-17497A	Acebutolol hydrochloride	Antagonist	99.63%	否
HY-17042	Cetirizine	Antagonist	99.51%	是
HY-14300	Vilanterol	Agonist	99.30%	否
HY-N0138	Theobromine	Inhibitor	99.78%	否
HY-B0111	Drospirenone	Agonist	98.45%	否
HY-12798B	Netarsudil hydrochloride	Inhibitor	99.77%	否
HY-B1114	Gliquidone		99.52%	否
HY-B0004	Doxofylline		99.65%	是
HY-12798A	Netarsudil dimesylate		99.56%	否
HY-14301	Olodaterol	Agonist	98.47%	否
HY-B0659	Brimonidine	Agonist	99.99%	是
HY-14301A	Olodaterol hydrochloride	Agonist	98.87%	否
HY-A0295	(R)-Propranolol hydrochloride	Antagonist	99.36%	否
HY-B1486	Oxprenolol hydrochloride	Antagonist	99.86%	否
HY-B1276	Metaproterenol hemisulfate	Agonist	99.86%	否
HY-B0166R	L-Ascorbic acid (Standard)		99.97%	否
HY-14806A	Teneligliptin hydrobromide	Inhibitor	99.99%	否
HY-16216	Gabapentin enacarbil	Inhibitor	≥95.0%	是
HY-10162R	Olaparib (Standard)		/	否
HY-B0240R	Disulfiram (Standard)		/	否
HY-B1016	Trapidil	Inhibitor	≥98.0%	否
HY-12798	Netarsudil	Inhibitor	98.78%	否
HY-13715C	Norepinephrine tartrate		99.45%	否
HY-13715R	Norepinephrine (Standard)		/	否
HY-B0010A	Arformoterol	Agonist	99.96%	否
HY-B0522R	Ampicillin (Standard)	Inhibitor	/	否
HY-N6810R	Thymol (Standard)		/	否
HY-B0246R	Carbamazepine (Standard)		/	否
HY-U00205	Dopexamine hydrochloride	Agonist	99.71%	否
HY-Y0320R	Dimethyl sulfoxide (Standard)	Inhibitor	/	否
HY-12432R	Gilteritinib (Standard)	Inhibitor	/	否
HY-17503R	Metoprolol (Standard)		/	否
HY-N0717R	L-Valine (Standard)		/	否
HY-W009156R	Citric acid (tripotassium hydrate) (Standard)	Inhibitor	/	否
HY-101474AR	Zanubrutinib (Standard)	Inhibitor	/	否
HY-10201R	Sorafenib (Standard)		99.71%	否
HY-12215R	Lorlatinib (Standard)		/	否
HY-122365R	Inositol nicotinate (Standard)		/	否
HY-12515AR	Nicardipine hydrochloride (Standard)		/	否
HY-15388R	Tazarotene (Standard)	Agonist	/	否
HY-17363R	Dimethyl fumarate (Standard)		/	否
HY-B0116R	Stavudine (Standard)		/	否
HY-B0210AR	Cefoperazone (sodium salt) (Standard)	Inhibitor	/	否
HY-B0354AR	Urapidil hydrochloride (Standard)		/	否
HY-B0592R	Trandolapril (Standard)	Inhibitor	/	否
HY-B1222R	Sisomicin (sulfate) (Standard)	Inhibitor	/	否
HY-15746A	Dobutamine	Agonist	/	否
HY-15746B	Dobutamine tartrate	Agonist	/	否
HY-19638	Cangrelor	Antagonist	/	否
HY-13570CR	Betamethasone disodium phosphate (Standard)		/	否
HY-13613R	Dutasteride (Standard)		/	否
HY-17440R	Rocuronium (Bromide) (Standard)		/	否
HY-17497	Acebutolol	Antagonist	/	否
HY-17508R	Clarithromycin (Standard)	Inhibitor	/	否
HY-76847R	Chenodeoxycholic Acid (Standard)	Activator	/	否
HY-B0010D	Arformoterol tartrate	Agonist	/	否
HY-B0131R	Prostaglandin E1 (Standard)	Agonist	/	否
HY-B0220R	Erythromycin (Standard)	Inhibitor	/	否
HY-B0313R	Hydroxyurea (Standard)		/	否
HY-B0345AR	ATP (disodium) (Standard)		/	否
HY-B0425AR	Novobiocin (sodium) (Standard)		/	否
HY-B0425R	Novobiocin (Standard)		/	否
HY-B0535AR	Ethambutol (dihydrochloride) (Standard)	Inhibitor	/	否
HY-B0659S	Brimonidine-d4	Agonist	/	否
HY-B0711R	Carglumic Acid (Standard)	Activator	/	否
HY-B1001	Todralazine	Inhibitor	/	否
HY-B1037R	Salbutamol (Standard)		/	否
HY-B1095R	Chlormadinone acetate (Standard)	Agonist	/	否
HY-B1486A	Oxprenolol	Antagonist	/	否
HY-B2227BR	Lactate (sodium) (Standard)		/	否
HY-N0067R	γ-Aminobutyric acid (Standard)	Agonist	/	否
HY-N0305R	5-Aminolevulinic acid (hydrochloride) (Standard)		/	否
HY-N0603R	20(S)-Ginsenoside Rg3 (Standard)	Inhibitor	/	否
HY-P0004R	Lysipressin (Standard)	Activator	/	否
HY-16752R	Relebactam (Standard)	Inhibitor	/	否
HY-17452AR	Cefditoren Pivoxil (Standard)	Inhibitor	/	否
HY-90003AR	Tianeptine sodium salt (Standard)	Agonist	/	否
HY-B0010E	Arformoterol maleate	Agonist	/	否
HY-B0129R	Aztreonam (Standard)	Inhibitor	/	否
HY-B0586R	Methylcobalamin (Standard)		/	否
HY-B0644R	Sucralfate (Standard)	Inhibitor	/	否
HY-B1428R	2-Ethoxybenzamide (Standard)	Activator	/	否
HY-N0184R	Glycyrrhizic acid (Standard)	Inhibitor	/	否
HY-N0193R	Artesunate (Standard)		/	否
HY-N0470R	L-Lysine (hydrochloride) (Standard)	Inhibitor	/	否
HY-N0550R	(-)-β-Pinene (Standard)	Inhibitor	/	否
HY-N1615	1beta-Hydroxy-beta-eudesmol		/	否
HY-U00244	Benzquinamide	Inhibitor	/	否

Clinical Phase

生物活性分子 (40)

目录号	产品名	作用方式	纯度	Phase
HY-15758	3,3'-Diindolylmethane		99.93%	Phase 4
HY-B0236R	6-Aminocaproic acid (Standard)	Inhibitor	/	Phase 4
HY-N0378R	D-Mannitol (Standard)		/	Phase 4
HY-N0593R	Deoxycholic acid (Standard)	Activator	/	Phase 4
HY-10211	Tanespimycin		99.01%	Phase 3
HY-13591	Piclidenoson		99.28%	Phase 3
HY-108449	Acoltremon	Agonist	99.90%	Phase 3
HY-12365	Namodenoson	Agonist	99.75%	Phase 3
HY-50289	Sorbinil	Inhibitor	99.85%	Phase 3
HY-Y0261A	Ammonium sulphate,≥99.0%,AR		99.3%	Phase 3
HY-15314	Ranirestat	Inhibitor	96.10%	Phase 3
HY-101479	Iclaprim	Inhibitor	99.49%	Phase 3
HY-N0324R	Cholic acid (Standard)		/	Phase 3
HY-105122	Zanoterone	Antagonist	/	Phase 3
HY-138641	Bavdegalutamide	Inhibitor	99.64%	Phase 2
HY-111784	Inobrodib	Inhibitor	99.94%	Phase 2
HY-106178	PMX-53	Antagonist	99.98%	Phase 2
HY-153342	Luxdegalutamide	Degrader	98.94%	Phase 2
HY-129393	Etrumadenant	Antagonist	99.76%	Phase 2
HY-101978	Ciforadenant	Antagonist	99.85%	Phase 2
HY-101980	Imaradenant	Antagonist	99.68%	Phase 2
HY-158101	BMS-986365	Degrader	99.92%	Phase 2
HY-100186	GSK-2881078	Modulator	99.74%	Phase 2
HY-15996	Seviteronel		99.83%	Phase 2
HY-123875A	Ralaniten triacetate	Inhibitor	98.79%	Phase 2
HY-109139	Taminadenant	Antagonist	99.84%	Phase 2
HY-115282A	JNJ-63576253	Antagonist	99.22%	Phase 2
HY-11027	MK-0773	Inhibitor	99.92%	Phase 2
HY-108235A	Lanicemine dihydrochloride	Antagonist	99.94%	Phase 2
HY-19436	Solabegron	Agonist	99.89%	Phase 2
HY-115282	JNJ-63576253 free base	Antagonist	/	Phase 2
HY-106186	GW-493838	Agonist	/	Phase 2
HY-106303	YT 146	Agonist	/	Phase 2
HY-16055	Silatecan	Inhibitor	/	Phase 2
HY-W039896	Propargyl a-D-mannopyranoside		/	Phase 2
HY-U00371	AR-08	Agonist	/	Phase 2
HY-103169	SCH442416	Antagonist	99.68%	Phase 1
HY-16079	AZD3514	Inhibitor	99.00%	Phase 1
HY-N2037	Higenamine		98.91%	Phase 1
HY-125639	(rac)-AR-13503	Inhibitor	/	Phase 1

抗体抑制剂 (2)

目录号	产品名	作用方式	纯度	Phase
HY-P99551	Tosatoxumab		95.00%	Phase 3
HY-P99450	Avdoralimab	Inhibitor	95.16%	Phase 2

Pre-clinical Phase

生物活性分子 (563)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-13248	AR-C155858	Inhibitor	99.62%	否
HY-145388	AU-15330		99.57%	否
HY-134923	CA77.1	Inducer	99.98%	否
HY-19532	ZM241385	Antagonist	99.26%	否
HY-W187305	MASM7		99.56%	否
HY-101106	AR7	Antagonist	99.38%	否
HY-10512	AR-A014418	Inhibitor	99.14%	否
HY-Y0649	Lithium chloride, 99.3%-T		99.3%	否
HY-135794	11-Ketodihydrotestosterone	Agonist	98.03%	否
HY-W015061	Phenylacetylglycine		99.63%	否
HY-N0790	Lupeol		≥98.0%	否
HY-138161	JR14a	Antagonist	99.59%	否
HY-110136A	PMX 205 Trifluoroacetate	Antagonist	99.50%	否
HY-116522	AR420626		98.29%	否
HY-12111	BMS-564929	Agonist	98.17%	否
HY-130492	ARCC-4	Inhibitor	99.88%	否
HY-N0236	Corylin	Inhibitor	99.97%	否
HY-145479	PROTAC AR-V7 degrader-1	Inhibitor	99.34%	否
HY-N1943	Ailanthone	Inhibitor	99.76%	否
HY-110126	AR-C118925XX	Antagonist	≥99.0%	否
HY-148141	JPE-1375	Antagonist	99.94%	否
HY-N0166	Gramine		99.63%	否
HY-N0528	Linarin	Inhibitor	98.00%	否
HY-Y0537	Potassium chloride, AR, 99.5%		99.6%	否
HY-19334	L755507	Agonist	98.33%	否
HY-136242	UT-34	Degrader	98.61%	否
HY-116501	VPC-14449	Inhibitor	99.71%	否
HY-N0092S2	Inosine-13C5	Agonist	99.90%	否
HY-10547	OSU-03012		98.88%	否
HY-100348	EPI-001		98.87%	否
HY-101986	BIIE-0246	Antagonist	99.10%	否
HY-109070	Ralaniten	Antagonist	99.78%	否
HY-148771	MTX-23		99.90%	否
HY-P1345A	TLQP-21 TFA	Agonist	99.90%	否
HY-Y0332B	Potassium dihydrogen phosphate, AR,99.5%		99.60%	否
HY-150102	EPI-7170	Antagonist	99.86%	否
HY-114936	Piericidin A	Inhibitor	≥99.0%	否
HY-12023	GTx-007	Modulator	99.67%	否
HY-P0298A	[Des-Arg9]-Bradykinin acetate	Agonist	99.95%	否
HY-13265	AR-42	Inducer	98.69%	是
HY-N2908	Atraric acid		99.94%	否
HY-W093399	Ammonium bicarbonate,AR,99%		≥99.0%	否
HY-121251	BI-167107	Agonist	99.98%	否
HY-132292	ARD-2128	Inhibitor	99.40%	否
HY-13631R	Exatecan (Standard)	Inhibitor	/	否
HY-133020	ARD-266	Inhibitor	99.62%	否
HY-112895	UT-155	Antagonist	99.55%	否
HY-123012	Lubabegron	Modulator	98.21%	否
HY-12798C	AR-13503		96.74%	否
HY-145709	Ar-V7-IN-1	Inhibitor	99.88%	否
HY-112052	Aminomalonic acid		98.87%	否
HY-145237	BM213	Agonist	99.81%	否
HY-153152	DPTN dihydrochloride	Antagonist	98.66%	否
HY-108250	(R)-Bicalutamide	Antagonist	99.94%	否
HY-112257	S-23	Modulator	99.93%	否
HY-131498	MOCAc-PLGL(Dpa)AR		99.86%	否
HY-149433	BWA-522	Inducer	99.93%	否
HY-70002B	Enzalutamide carboxylic acid		98.11%	否
HY-110012	SCH-202676 hydrobromide	Modulator	96.81%	否
HY-15564	AR 231453	Agonist	99.70%	否
HY-114402	ARD-69	Antagonist	99.75%	否
HY-124292	Honokiol DCA	Inhibitor	98.37%	否
HY-161409	SC912		99.13%	否
HY-117669	VPC-14228	Inhibitor	99.92%	否
HY-120006A	(rel)-AR234960	Agonist	99.42%	否
HY-122611A	CSRM617 hydrochloride		99.97%	否
HY-130992	Androgen receptor antagonist 1	Antagonist	99.71%	否
HY-133045	VHL Ligand 8		98.04%	否
HY-B0845	Prochloraz		99.77%	否
HY-19319	MI-136		99.04%	否
HY-19337	Ketodarolutamide	Antagonist	98.72%	否
HY-139644	MIPS521	Agonist	98.21%	否
HY-N4089	Quercetin 3-gentiobioside	Inhibitor	99.92%	否
HY-30756	tert-Butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate		99.89%	否
HY-103190	MRS1220	Antagonist	99.50%	否
HY-139659	ARD-61		99.68%	否
HY-153918	(R)-SKBG-1	Inhibitor	99.50%	否
HY-158113	CBPD-409	Degrader	/	否
HY-18776	A2AR-agonist-1	Agonist	99.90%	否
HY-110060	NDT 9513727	Antagonist	99.35%	否
HY-111151	AR-9281	Inhibitor	99.43%	否
HY-111809	N6-Ethyladenosine	Agonist	99.90%	否
HY-116214	Cyprodinil		99.36%	否
HY-16758	Verosudil	Inhibitor	99.18%	否
HY-B1876	Nicosulfuron	Inhibitor	97.15%	否
HY-W110883	Xylenol orange tetrasodium salt, IND		≥95.0%	否
HY-100554	BMY 7378		99.92%	否
HY-101986A	BIIE-0246 hydrochloride	Antagonist	≥99.0%	否
HY-103180	2'-MeCCPA	Agonist	99.79%	否
HY-112256	ACP-105	Modulator	98.99%	否
HY-19569R	Upadacitinib (Standard)	Inhibitor	99.73%	否
HY-156111	ARD-1676	Degrader	99.36%	否
HY-102076	0990CL	Inhibitor	≥98.0%	否
HY-103162	ANR94	Antagonist	98.87%	否
HY-120018	VPC-13566	Inhibitor	99.87%	否
HY-12122A	AR-C102222 hydrochloride	Inhibitor	99.83%	否
HY-164373	SC428		≥98.0%	否
HY-19687	Zopolrestat	Inhibitor	99.92%	否
HY-70002S1	Enzalutamide-d6	Antagonist	99.74%	否
HY-W013249	Boc-piperazine-benzoic acid		97.42%	否
HY-130845A	AR antagonist 1 hydrochloride	Antagonist	99.53%	否
HY-131388	ABM-14		98.17%	否
HY-160777	VNPP433-3β	Degrader	98.01%	否
HY-B0573S1	Propranolol-d7 (ring-d7)	Antagonist	99.38%	否
HY-B0846	Dimethomorph	Inhibitor	99.13%	否
HY-N2673	5-Heptadecylresorcinol	Activator	99.83%	否
HY-101039A	AR-M 1000390 hydrochloride	Agonist	99.05%	否
HY-101393A	CGP 12177 hydrochloride	Modulator	99.69%	否
HY-101854	N6-(2-Phenylethyl)adenosine	Agonist	99.41%	否
HY-117992	BR103		99.75%	否
HY-135483A	AR-R17779 hydrochloride	Agonist	≥99.0%	否
HY-14250	PF-998425	Antagonist	98.31%	否
HY-149862	ARD-2051	Degrader	98.19%	否
HY-16060S	Apalutamide-d4	Antagonist	99.90%	否
HY-161369	CBPD-268	Degrader	/	否
HY-162412	PROTAC AR/AR-V7 degrader-1		99.72%	否
HY-B0031S1	Quetiapine-d4 hemifumarate		99.69%	否
HY-B1001A	Todralazine hydrochloride	Inhibitor	99.87%	否
HY-B1866	Linuron	Antagonist	99.88%	否
HY-N0138S1	Theobromine-d3	Inhibitor	99.78%	否
HY-N7045	Isosilybin B		99.32%	否
HY-101300	Cirazoline hydrochloride	Agonist	99.65%	否
HY-111848A	PROTAC AR Degrader-4 TFA	Inhibitor	99.26%	否
HY-133127	AR453588	Activator	99.84%	否
HY-103245	Cl-4AS-1	Agonist	99.2%	否
HY-105318	LGD-2226	Modulator	98.43%	否
HY-130353	Desethylamiodarone hydrochloride		≥99.0%	否
HY-134851	HIV-1 inhibitor-6	Inhibitor	98.91%	否
HY-135732	SK33	Antagonist	99.81%	否
HY-141487	CLP-3094	Inhibitor	≥95.0%	否
HY-151231	6-Hydroxyluteolin	Inhibitor	98.15%	否
HY-160020	ET516	Inhibitor	/	否
HY-17042S	Cetirizine-d4	Antagonist	≥98.0%	否
HY-17042S1	Cetirizine-d8	Antagonist	98.37%	否
HY-B0573BS	Propranolol-d7	Antagonist	≥99.0%	否
HY-B1486S	Oxprenolol-d7 hydrochloride	Antagonist	98.25%	否
HY-N0092S	Inosine-2,8-d2	Agonist	99.69%	否
HY-N2407R	1,4-Butanediamine (Standard)		/	否
HY-N6703	ar-Turmerone	Inducer	98.52%	否
HY-RS00884	Ar Mouse Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-W109613	Methyl dehydroabietate	Inhibitor	99.89%	否
HY-135794S	11-Ketodihydrotestosterone-d3	Agonist	99.00%	否
HY-151239	ONT-993	Inhibitor	99.85%	否
HY-W653723	N-Nitrosodicyclohexylamine	Antagonist	≥99.0%	否
HY-111848	PROTAC AR Degrader-4	Inhibitor	/	否
HY-N4068R	Glucoraphanin (Standard)		/	否
HY-111372A	(Rac)-Finerenone	Antagonist	99.66%	否
HY-103183	CV1808	Agonist	≥98.0%	否
HY-103246	TFM-4AS-1		99.96%	否
HY-106954	Upidosin	Antagonist	99.58%	否
HY-110136	PMX 205	Antagonist	/	否
HY-111145	RD162	Antagonist	99.69%	否
HY-113430	5-n-Heneicosylresorcinol	Inhibitor	/	否
HY-119996A	AR-C141990 hydrochloride	Inhibitor	≥98.0%	否
HY-122917	Danshenol A	Inhibitor	99.67%	否
HY-12715S	Yohimbine-13C,d3	Antagonist	≥99.0%	否
HY-131272	Febuxostat dicarboxylic acid impurity		98.76%	否
HY-131280	Devaleryl Valsartan Impurity		99.99%	否
HY-133776	Rivastigmine carbamate impurity	Inhibitor	99.98%	否
HY-134983	Thalidomide-Piperazine 5-fluoride	Inducer	96.47%	否
HY-136596	Apalutamide-COOH		99.14%	否
HY-14250A	(Rac)-PF-998425	Antagonist	99.68%	否
HY-144127	AR antagonist 3	Antagonist	99.96%	否
HY-147291	VPC-70063		99.92%	否
HY-147907	Adenosine receptor inhibitor 1	Inhibitor	/	否
HY-151596	MAO-A/5-HT2AR-IN-1	Inhibitor	99.71%	否
HY-151604	Transketolase-IN-3	Inhibitor	98.52%	否
HY-153015	AAZ-A 154	Antagonist	≥98.0%	否
HY-159190	HRX-0233	Inhibitor	/	否
HY-16060S1	Apalutamide-d3		/	否
HY-16060S2	Apalutamide-13C,d3	Antagonist	99.90%	否
HY-160887	FPT	Agonist	98.06%	否
HY-161741	VinclozolinM2-2204	Degrader	98.00%	否
HY-162325	WJ-39		99.60%	否
HY-163340	GA32	Inhibitor	99.67%	否
HY-70002S	Deutenzalutamide		99.81%	否
HY-77734	AR-C133913XX		99.76%	否
HY-90009D	(6S,12aR)-Tadalafil	Inhibitor	99.34%	否
HY-N4232	Clematichinenoside AR	Inducer	≥99.0%	否
HY-N7962	Cornoside	Inhibitor	≥96.0%	否
HY-N9917	Galloylalbiflorin	Antagonist	≥95.0%	否
HY-P0298	[Des-Arg9]-Bradykinin	Agonist	/	否
HY-P5213	Vasopressin Dimer (parallel) (TFA)	Activator	99.55%	否
HY-P5506	C5a Receptor agonist, W5Cha	Agonist	99.50%	否
HY-U00244A	Benzquinamide hydrochloride	Inhibitor	99.14%	否
HY-W012953	Diethylamine hydrochloride		≥98.0%	否
HY-W015061S	N-(Phenylacetyl-d5)glycine		≥99.0%	否
HY-W110794	Crystal violet indicator (0.0-2.0), IND		/	否
HY-105542R	Niaprazine (Standard)	Antagonist	/	否
HY-19346	AR-13324 analog mesylate		≥98.0%	否
HY-P10639	C5aR2 agonist P32	Agonist	99.82%	否
HY-W060074	1-Acetyl-β-carboline		97.04%	否
HY-W111193A	Phosphotungstic acid hydrate,AR		/	否
HY-130845	AR antagonist 1		/	否
HY-14561	Idazoxan		/	否
HY-N6818R	5,7,4'-Trimethoxyflavone (Standard)		/	否
HY-101514	β3-AR agonist 1	Agonist	/	否
HY-125839	OP-3633	Antagonist	/	否
HY-133127A	AR453588 hydrochloride	Activator	/	否
HY-130353S	Desethyl Amiodarone-d4 hydrochloride		/	否
HY-14249S	Bicalutamide-d4		/	否
HY-N0138S	Theobromine-d6	Inhibitor	≥98.0%	否
HY-100348R	EPI-001 (Standard)		/	否
HY-100661	Cetirizine Impurity D	Antagonist	/	否
HY-100665R	Dehydroaripiprazole (Standard)	Agonist	/	否
HY-100665S	Dehydroaripiprazole-d8	Agonist	/	否
HY-101986C	BIIE-0246 dihydrochloride	Antagonist	/	否
HY-10273	Atecegatran metoxil	Inhibitor	/	否
HY-10275A	Atecegatran TFA	Inhibitor	/	否
HY-103177	PSB-10 hydrochloride	Inhibitor	/	否
HY-103203	ST91	Agonist	99.75%	否
HY-10512S	AR-A014418-d3	Inhibitor	/	否
HY-106684A	Ridazolol hydrochloride	Antagonist	/	否
HY-106769A	(3aR,9aR)-Fluparoxan hydrochloride		/	否
HY-107819R	5α-Cholestan-3β-ol (Standard)		/	否
HY-108633	BYK 49187	Inhibitor	/	否
HY-108665	AR-C66096 tetrasodium		/	否
HY-109139A	Taminadenant mesylate	Antagonist	/	否
HY-110202	MRS5698	Agonist	/	否
HY-111044	(+)-JNJ-37654032	Modulator	/	否
HY-112006	(S)-ar-Curcumene		/	否
HY-113486R	Lathosterol (Standard)		/	否
HY-113575	Dehydroaripiprazole hydrochloride	Agonist	/	否
HY-113781	Ractopamine	Agonist	/	否
HY-115940	Aldose reductase-IN-2	Inhibitor	/	否
HY-115977	Aldose reductase-IN-3	Inhibitor	/	否
HY-116042	FSCPX	Antagonist	99.72%	否
HY-116214R	Cyprodinil (Standard)		/	否
HY-116214S	Cyprodinil-d5		/	否
HY-116214S1	Cyprodinil-13C6		/	否
HY-116379	RS-100329	Antagonist	/	否
HY-117239	SB-206606	Agonist	/	否
HY-117953	RU 59063	Inhibitor	/	否
HY-117971	BVT173187		/	否
HY-118260	Phendioxan		/	否
HY-119806	TMPPAA	Agonist	/	否
HY-119993	AR03	Inhibitor	/	否
HY-119996	AR-C141990		/	否
HY-120208	MK204	Inhibitor	/	否
HY-120652	A3AR antagonist 3	Antagonist	/	否
HY-12099	A3AR antagonist 2	Antagonist	/	否
HY-121094	Androgen receptor allosteric antagonist 1	Antagonist	/	否
HY-121588	IMTPPE	Inhibitor	/	否
HY-12172	MK-8141		/	否
HY-122108	Ilicicolin A	Inducer	/	否
HY-122231	MRS3558	Agonist	/	否
HY-122611	CSRM617		/	否
HY-122963	Danshenol B		/	否
HY-123012A	Lubabegron fumarate	Antagonist	/	否
HY-123163	JNJ-1250132		/	否
HY-123308	VPC13163	Inhibitor	/	否
HY-123310	JNJ-26146900	Antagonist	/	否
HY-124270	Sibenadet hydrochloride	Agonist	/	否
HY-125065	MK-4541		/	否
HY-126464	Estromustine	Modulator	/	否
HY-12716	BRL-44408	Antagonist	/	否
HY-128934	Antitumor agent-2		/	否
HY-130353R	Desethylamiodarone hydrochloride (Standard)		/	否
HY-131279	Olmesartan ethyl ester		/	否
HY-133044	Boc-Pip-alkyne-Ph-COOH		/	否
HY-133046	VHL Ligand-Linker Conjugates 17		/	否
HY-133862	SCH-202676		/	否
HY-13613S	Dutasteride-13C6		/	否
HY-13613S2	Dutasteride-13C,15N,d		/	否
HY-136960	β2AR antagonist 1	Antagonist	/	否
HY-13715S	(Rac)-Norepinephrine-d3 formate		/	否
HY-139104	Thailanstatin D		/	否
HY-139694	hA3AR agonist 1	Agonist	/	否
HY-139970	VPC-13789	Inhibitor	/	否
HY-141865	Adenosine receptor antagonist 1	Antagonist	/	否
HY-14249S1	Bicalutamide-d5		/	否
HY-142923	AR antagonist 2	Antagonist	/	否
HY-14300AS	Vilanterol-d4 trifenatate	Agonist	/	否
HY-143471	WNY0824		/	否
HY-143535	HG122		/	否
HY-144115	A1AR antagonist 1	Antagonist	/	否
HY-144116	A1AR antagonist 2	Antagonist	/	否
HY-144672	A2A receptor antagonist 2	Antagonist	/	否
HY-145308	Heterobivalent ligand-1		/	否
HY-145406	IHCH-3064	Inhibitor	/	否
HY-145480	Silodosin Glucuronide sodium		/	否
HY-145698	UCSF678	Agonist	/	否
HY-145699	UCSF686		/	否
HY-145706	A2A/A1 AR antagonist-1	Antagonist	/	否
HY-145862	5-HT6/5-HT2AR antagonist-1	Agonist	/	否
HY-146026	Androgen receptor antagonist 3	Antagonist	/	否
HY-146027	Androgen receptor antagonist 4	Antagonist	/	否
HY-146397	TD-802	Inhibitor	/	否
HY-146456	A1AR antagonist 3	Antagonist	/	否
HY-146457	A3AR antagonist 1	Antagonist	/	否
HY-146478	A1/A3 AR antagonist 1	Antagonist	/	否
HY-146479	A1/A3 AR antagonist 2		/	否
HY-146494	Androgen receptor antagonist 5	Antagonist	/	否
HY-146979	hA2A/hCA XII modulator 1		/	否
HY-147100	α1A-AR Degrader 9c	Inhibitor	/	否
HY-147261	B026	Inhibitor	/	否
HY-147541	A2A/A3 AR antagonist-1	Antagonist	/	否
HY-147543	A1AR antagonist 4	Antagonist	/	否
HY-147544	A1AR antagonist 5	Antagonist	/	否
HY-147545	A1AR antagonist 6	Antagonist	/	否
HY-147585	C5aR-IN-1		/	否
HY-147586	C5aR-IN-2		/	否
HY-147587	C5aR-IN-3		/	否
HY-147706	AR524		/	否
HY-147875	Aldose reductase-IN-6	Inhibitor	/	否
HY-147908	Adenosine receptor inhibitor 2	Inhibitor	/	否
HY-148252	ADRA1D receptor antagonist 1 free base	Antagonist	/	否
HY-148361	Fluorogen binding modulator-1		/	否
HY-148524	β2AR/M-receptor agonist-1		/	否
HY-148525	PF-4348235		/	否
HY-148526	β2AR/M3-receptor agonist-1	Agonist	/	否
HY-148533	β2AR agonist /M-receptor antagonist-1		/	否
HY-148777	A031	Degrader	/	否
HY-14897	Rezatomidine	Agonist	/	否
HY-149127	Rosolutamide		/	否
HY-149434	PROTAC AR-NTD degrader 1	Inducer	/	否
HY-149727	β2AR agonist 2	Agonist	/	否
HY-149728	β2AR agonist 3	Agonist	/	否
HY-149914	WCA-814	Degrader	/	否
HY-149916	A2AR-antagonist-1	Antagonist	/	否
HY-150025	(4aS,8aR)-NPD-001		/	否
HY-15011	L-372662	Antagonist	98.70%	否
HY-151266	AR antagonist 4	Antagonist	/	否
HY-151899	A3AR modulator 1	Agonist	/	否
HY-152524	Androgen receptor antagonist 7	Antagonist	/	否
HY-153333	A1/A3 AR antagonist 3	Antagonist	/	否
HY-153519	WWL0245	Inhibitor	/	否
HY-155183	A3AR agonist 1	Agonist	/	否
HY-155184	A3AR agonist 2	Agonist	/	否
HY-155543	Anticancer agent 135	Antagonist	/	否
HY-155666	YXG-158	Degrader	/	否
HY-155772	LUF7690		/	否
HY-156084	LL-K9-3		/	否
HY-156751	PROTAC AR Degrader-6	Degrader	/	否
HY-156983	MRS 5980		/	否
HY-157425	5-HT2CR agonist 1	Agonist	/	否
HY-157455	AR antagonist 5		/	否
HY-157491	K2-B4-5e	Degrader	/	否
HY-157796	β2AR agonist 4	Agonist	/	否
HY-157916	ARP		/	否
HY-157918	Carboxy-EG6-hexadecanethiol		/	否
HY-158057	A2AR/A2BR antagonist 1	Antagonist	/	否
HY-158179	A3AR agonist 3	Agonist	/	否
HY-158180	A3AR agonist 4	Agonist	/	否
HY-158181	A3AR agonist 5	Agonist	/	否
HY-159096	Apoptosis inducer 21	Inducer	/	否
HY-159639	BAY-2925976	Inhibitor	/	否
HY-159942	5-HT7R antagonist 3		/	否
HY-160221	PROTAC AR Degrader-7		/	否
HY-160262	AR/BET protein degrader-1	Degrader	/	否
HY-160547	PROTAC AR Degrader-5		/	否
HY-160680	AR antagonist 6	Inhibitor	/	否
HY-160692	AR antagonist 7	Antagonist	/	否
HY-161717	MRS5663	Agonist	/	否
HY-161718	MRS8028	Agonist	/	否
HY-161810	MRS8247	Modulator	/	否
HY-161836	α2AR agonist 1	Agonist	/	否
HY-162083	CB2R/5-HT1AR agonist 1	Agonist	/	否
HY-162241	SJH1-62B	Degrader	/	否
HY-162585	5-HT1AR agonist 1	Agonist	/	否
HY-162620	α2A-AR agonist 1	Agonist	/	否
HY-162659	β2AR ligand 1		/	否
HY-162702	AZ'3137	Degrader	/	否
HY-163363	β-AR antagonist 2	Antagonist	/	否
HY-163378	C5aR1 antagonist 1	Antagonist	/	否
HY-163379	C5aR1 antagonist 2	Antagonist	/	否
HY-163485	AR antagonist 8	Inhibitor	/	否
HY-163510	AR/AR-V7-IN-1	Inhibitor	/	否
HY-163632	EGFR-IN-112	Inhibitor	/	否
HY-163641	AR Degrader-1	Degrader	/	否
HY-163813	AR Degrader-2	Degrader	/	否
HY-163940	LX1	Inhibitor	/	否
HY-163978	YGZ-331	Activator	/	否
HY-16758A	Verosudil hydrochloride	Inhibitor	/	否
HY-167905	ATL444	Antagonist	/	否
HY-168141	Androgen receptor antagonist 11	Antagonist	/	否
HY-169349	Androgen receptor antagonist 12	Antagonist	/	否
HY-169394	5-HT1AR agonist 2		/	否
HY-169975	tert-Butyl 4-(4-(piperazin-1-ylmethyl)piperidin-1-yl)benzoate		/	否
HY-169976	E3 Ligase Ligand-linker Conjugate 140		/	否
HY-17042AS1	Cetirizine-d8 dihydrochloride	Antagonist	/	否
HY-17497S	Acebutolol-d7	Antagonist	/	否
HY-18569R	3-Indoleacetic acid (standard)		/	否
HY-19436A	Solabegron hydrochloride	Agonist	/	否
HY-19532S	ZM241385-d7	Antagonist	/	否
HY-78542S	Deshydroxyethoxy Ticagrelor-d7		/	否
HY-B0010AS	Formoterol-d3	Agonist	/	否
HY-B0031S3	Quetiapine-d8 hemifumarate		/	否
HY-B0075R	Melatonin (standard)		/	否
HY-B0076S	Bisoprolol-d7 hemifumarate	Inhibitor	/	否
HY-B0143R	Niacin (standard)	Inducer	/	否
HY-B0172R	Lithocholic acid (Standard)		/	否
HY-B0573S	Propranolol-d7 hydrochloride	Antagonist	98.02%	否
HY-B0765R	Dehydroepiandrosterone sulfate (sodium salt) (Standard)		/	否
HY-B0834R	(±)-Indoxacarb (Standard)	Inhibitor	/	否
HY-B0846S	Dimethomorph-d8		/	否
HY-B1114S	Gliquidone-d6		/	否
HY-B1276A	Metaproterenol	Agonist	/	否
HY-B1486AS	Oxprenolol-d7	Antagonist	/	否
HY-B1562	Bopindolol		/	否
HY-B1562B	Bopindolol (malonate)		/	否
HY-B1562C	Bopindolol fumarate		/	否
HY-B2219R	Stearic acid (Standard)		/	否
HY-D1379	Azophloxine		/	否
HY-D1606	BODIPY FL prazosin	Inhibitor	99.71%	否
HY-E70333	Rapidase Revelation Aroma (AR2000), Aspergillus niger		/	否
HY-N0009R	Geniposide (Standard)		/	否
HY-N0043R	Ginsenoside Rd (Standard)	Inhibitor	/	否
HY-N0045R	Ginsenoside Rg1 (Standard)		/	否
HY-N0092S1	Inosine-13C	Agonist	/	否
HY-N0092S3	Inosine-13C10,15N4	Agonist	/	否
HY-N0123R	Aloin-A (Standard)	Inhibitor	/	否
HY-N0166R	Gramine (Standard)		/	否
HY-N0181R	Ergosterol (Standard)		/	否
HY-N0373R	Licochalcone B (Standard)		/	否
HY-N0376R	Liquiritin (Standard)		/	否
HY-N0511R	Aristolochic acid B (Standard)		/	否
HY-N0545R	Taurocholic acid (sodium) (Standard)	Agonist	/	否
HY-N0549R	(-)-α-Pinene (Standard)		/	否
HY-N0604R	Ginsenoside Rh1 (Standard)	Inhibitor	/	否
HY-N0728R	α-Linolenic acid (Standard)	Inhibitor	/	否
HY-N0904R	Ginsenoside C-K (Standard)	Inhibitor	/	否
HY-N10906	(4R,4aS,5aS,6aR,6bS,7aR)-4-Hydroxy-3,6b-dimethyl-5-methylene-4,4a,5,5a,6,6a,7,7a-octahydrocyclopropa[2,3]indeno[5,6-b]furan-2(6bH)-one		/	否
HY-N11163	(Z)-(1R,3R,4R,4aS,8R,8aR)-3,4,8,8a-Tetramethyl-7-oxo-4-(2-(5-oxo-2,5-dihydrofuran-3-yl)ethyl)decahydronaphthalen-1-yl 2-methylbut-2-enoate		/	否
HY-N1178R	Taraxasterol (Standard)		/	否
HY-N1363R	Royal Jelly acid (Standard)		/	否
HY-N1459R	Campesterol (Standard)		/	否
HY-N1964R	Gibberellic acid (Standard)		/	否
HY-N2327R	Oleamide (Standard)		/	否
HY-N2497R	Isoliquiritin apioside (Standard)	Inhibitor	/	否
HY-N3716	Dehydroglyasperin D	Inhibitor	/	否
HY-N3962R	Glycyrrhisoflavone (Standard)	Inhibitor	/	否
HY-N6700R	Aflatoxin M2 (Standard)		/	否
HY-N6703S	ar-Turmerone-d3	Inducer	/	否
HY-N6883	6-Methoxytricin	Inhibitor	/	否
HY-N6947R	Lutein (Standard)	Inhibitor	/	否
HY-N7271R	Solanidine (Standard)		/	否
HY-P1129	AR-M1896	Agonist	/	否
HY-P1345	TLQP-21	Agonist	/	否
HY-P1640	(Trp63,Trp64)-C3a(63-77)	Agonist	/	否
HY-P3477	Mca-PLA-Nva-Dap(Dnp)-AR-NH2		/	否
HY-P5010	(D-Arg8)-Inotocin	Antagonist	/	否
HY-P5214	Vasopressin Dimer (anti-parallel) (TFA)	Activator	/	否
HY-R01656	hsa-miR-548ar-3p mimic		/	否
HY-R01656A	hsa-miR-548ar-3p agomir		/	否
HY-R01657	hsa-miR-548ar-5p mimic		/	否
HY-R01657A	hsa-miR-548ar-5p agomir		/	否
HY-RI01656	hsa-miR-548ar-3p inhibitor		/	否
HY-RI01656A	hsa-miR-548ar-3p antagomir		/	否
HY-RI01657	hsa-miR-548ar-5p inhibitor		/	否
HY-RI01657A	hsa-miR-548ar-5p antagomir		/	否
HY-RS00883	AR Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS00885	Ar Rat Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS01744	C3AR1 Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS01750	C5AR1 Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS01751	C5AR2 Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-W001132R	Indole (standard)		/	否
HY-W009082R	Methyl behenate (Standard)		/	否
HY-W010382R	Oxaloacetic acid (standard)	Inhibitor	/	否
HY-W013215R	Adrenic acid (Standard)		/	否
HY-W093399S	Ammonium bicarbonate-15N		/	否
HY-W134423A	Agar, microbiology tested, for cell culture (granular)		/	否
HY-W140282	Angiotensin II antipeptide	Inhibitor	/	否
HY-W350004	(+)-Arabinogalactan,from larch wood, 80%		/	否
HY-W471937	α1B-AR antagonist 1	Antagonist	/	否
HY-W540764	1,2-Phenylenediamine dihydrochloride, 99%		/	否
HY-W909149	TAAR1 agonist 3	Agonist	/	否
HY-Y0261AS	Ammonium sulphate-d8		/	否
HY-Y0261AS1	Ammonium sulphate,≥99.0%,AR-N152		≥98.0%	否
HY-Y0827	Barium carbonate,AR,99%		/	否
HY-Y0978S2	Boc-Glycine-2-13C	Antagonist	/	否
HY-10122S	Silodosin-d4	Antagonist	/	否
HY-101479S	Iclaprim-d6	Inhibitor	/	否
HY-101977B	(3aR)-Selitrectinib	Inhibitor	/	否
HY-10275	Atecegatran	Inhibitor	/	否
HY-103163	(±)-5'-Chloro-5'-deoxy-ENBA	Agonist	/	否
HY-106178D	PMX 53 monoacetate		/	否
HY-106684	Ridazolol	Antagonist	/	否
HY-106769B	(3aR,9aR)-Fluparoxan		/	否
HY-107567B	Carcinine dihydrochloride	Antagonist	/	否
HY-109030R	Dorzagliatin (Standard)	Activator	/	否
HY-111206	β3-AR agonist 3	Agonist	/	否
HY-111273	AR244555	Antagonist	/	否
HY-111372S	Finerenone-d3		/	否
HY-111372S1	Finerenone-d5	Antagonist	/	否
HY-114246	ONC1-13B		/	否
HY-114602	AR-C117977	Inhibitor	/	否
HY-115862	Benzo[c][1,8]naphthyridin-6(5H)-one	Inhibitor	/	否
HY-116065	CUMI-101	Agonist	/	否
HY-116508	MK 319	Inhibitor	/	否
HY-118375	Phenylbutyl isoselenocyanate	Inducer	/	否
HY-118944	L-748328	Antagonist	/	否
HY-119088	Estrogen receptor modulator 12		/	否
HY-12122	AR-C102222	Inhibitor	/	否
HY-122048	AR-C67085		/	否
HY-122053	Amidephrine hydrochloride	Inhibitor	/	否
HY-122177	MK181	Inhibitor	/	否
HY-123358	AR-H049020XX		/	否
HY-125602	MNI-444		/	否
HY-12605S	SAR107375-d11 Tartrate	Inhibitor	/	否
HY-129761	AR 17048		/	否
HY-131953	Androgen receptor-IN-3	Inhibitor	/	否
HY-134555	A3AR antagonist 4	Antagonist	/	否
HY-136702	L-97-1	Antagonist	/	否
HY-141614	1,2-Diarachidoyl-sn-glycero-3-phosphocholine		/	否
HY-153015A	AAZ-A 154 hydrobromide	Antagonist	/	否
HY-153015B	AAZ-A 154 hydrochloride	Antagonist	/	否
HY-153015C	AAZ-A 154 benzoate	Antagonist	/	否
HY-153015D	AAZ-A 154 mesylate	Antagonist	/	否
HY-154959A	(9R,12aR)-AZD4747		98.90%	否
HY-155467	MRS7935	Modulator	/	否
HY-15746S	(rac)-Dobutamine-d4 hydrochloride	Agonist	/	否
HY-15746S1	(rac)-Dobutamine-d6 hydrochloride	Agonist	/	否
HY-159686	Aclidinium	Agonist	/	否
HY-16060S3	Apalutamide-d7	Antagonist	/	否
HY-162851	Adenosine receptor agonist 1	Agonist	/	否
HY-164371	(+)-JJ-74-138	Antagonist	/	否
HY-164477	FL442	Modulator	/	否
HY-164552	ZNU-IMB-Z15		/	否
HY-164621	A3AR antagonist 5	Antagonist	98.17%	否
HY-165673S	9(S)-Hexahydrocannabinol-d9		/	否
HY-166876S	Nicergoline impurity 18-d4		/	否
HY-166887S	Tiotropium bromide impurity-d3		/	否
HY-166898S	trans Nonachlor-13C10		/	否
HY-166906S	cis-Nonachlor-13C10		/	否
HY-168168	(5aS,6R,6aR)-MK-8666		/	否
HY-168296	AR ligand-29		/	否
HY-168299	AR ligand-30		/	否
HY-168547S	AR89-d6	Inhibitor	/	否
HY-168697	AR ligand-37		/	否
HY-169966	Boc-CH2-O-(CH2)4-OTs		/	否
HY-169967	AR ligand-31		/	否
HY-400766	BWA-522 intermediate-2		99.87%	否
HY-401056	BWA-522 intermediate-3		/	否
HY-A0052S	(1S,3aR,6aS)-(2S)-2-Cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1R)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydrocyclopenta[c]pyrrole-1-carboxamide-d4		/	否
HY-B0488R	Clorsulon (Standard)	Inhibitor	/	否
HY-B1037B	Salbutamol adipate		/	否
HY-B1276S	Metaproterenol-d7 hemisulfate	Agonist	/	否
HY-D0889R	Glycylglycine (Standard)		/	否
HY-N0092S4	Inosine-13C3	Agonist	/	否
HY-N0337R	Eugenol (Standard)		/	否
HY-N0785R	Ginkgolide C (Standard)	Activator	/	否
HY-N12358	Isogermafurenolide		/	否
HY-N13308	8-Hydroxy-ar-turmerone		/	否
HY-N1445R	Isoquercitrin (Standard)	Inhibitor	/	否
HY-P10639A	C5aR2 agonist P32 acetate	Agonist	/	否
HY-W1003189	E3 ligase Ligand 42		/	否
HY-W110146	(3aS,4S,6aR)-Biotin-PEG4-Alkyne		99.93%	否
HY-W130878	4-Octylphenol	Activator	/	否
HY-W251598JR	Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard (Standard)	Inhibitor	/	否
HY-W341547	3,4-Dihydro-6,7-isoquinolinediol	Agonist	/	否
HY-W424779R	5-Carboxy-2′-deoxyuridine (Standard)		/	否
HY-W654262	10α-Methoxy-9,10-dihydrolysergol-d3		/	否
HY-W741999	Metaproterenol-d7-1 hemisulfate	Agonist	/	否
HY-W743954	Nicergoline impurity 11-d3		/	否
HY-W877989	BWA-522 intermediate-1		99.27%	否
HY-Y0278R	Chloranil (Standard)		/	否
HY-Y0739R	(1R)-α-Pinene (Standard)	Inhibitor	/	否
HY-101039	AR-M 1000390	Agonist	/	否
HY-107018	AR-A 2	Antagonist	/	否
HY-118678	MRS1186	Antagonist	/	否
HY-120090	MRS1177	Antagonist	/	否
HY-U00391	β3-AR agonist 2	Agonist	/	否